Table 4.

Relationship between adverse events of maintenance treatment and chemotherapy given before maintenance treatment

		Chemotherapy	Maintenance treatment		Chemotherapy	Maintenance treatment		Chemotherapy	Maintenance treatment
	Grade	Olaparib (N = 30)	Olaparib (N = 30)	P value	Olaparib plus bevacizumab (N = 27)	Olaparib plus bevacizumab (N = 27)	P value	Niraparib (N = 60)	Niraparib (N = 60)	P value
Anemia				0.39			0.013*			0.793
	1	12 (40.0%)	9 (30.0%)		8 (29.6%)	10 (37.1%)		17 (28.3%)	30 (50.0%)
	2	11 (36.7%)	11 (36.7%)		16 (59.3%)	6 (22.2%)		35 (58.3%)	21 (35.0%)
	3	7 (23.3%)	10 (33.3%)		3 (11.1%)	11 (40.7%)		8 (13.3%)	9 (15.0%)
Neutropenia				0.006*			0.020*			<0.001*
	0	2 (6.7%)	8 (26.7%)		2 (7.4%)	6 (22.2%)		7 (11.7%)	18 (30.0%)
	1	6 (20.0%)	5 (16.7%)		3 (11.1%)	7 (25.9%)		11 (18.3%)	21 (35.0%)
	2	7 (23.3%)	12 (40.0%)		9 (33.3%)	9 (33.3%)		14 (23.3%)	15 (25.0%)
	3	10 (33.3%)	5 (16.7%)		3 (11.1%)	5 (18.5%)		11 (18.3%)	6 (10.0%)
	4	5 (16.7%)	0 (0.0%)		10 (37.1%)	0 (0.0%)		17 (28.3%)	0 (0.0%)
Thrombocytopenia				0.15			0.552			0.17
	1	24 (80.0%)	26 (86.7%)		24 (88.9%)	24 (88.9%)		54 (90.0%)	53 (88.3%)
	2	4 (13.3%)	4 (13.3%)		2 (7.4%)	1 (3.7%)		5 (8.3%)	3 (5.0%)
	3	2 (6.7%)	0 (0.0%)		1 (3.7%)	2 (7.4%)		1 (1.7%)	1 (1.7%)
	4	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)		0 (0.0%)	3 (5.0%)
eGFR				0.037*			<0.001*			0.016*
	0	12 (40.0%)	5 (16.7%)		14 (51.9%)	2 (7.4%)		32 (53.3%)	13 (21.7%)
	1	9 (30.0%)	8 (26.7%)		7 (25.9%)	5 (18.5%)		9 (15.0%)	15 (25.0%)
	2	8 (26.7%)	16 (53.3%)		6 (22.2%)	19 (70.4%)		19 (31.7%)	29 (48.3%)
	3	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (3.7%)		0 (0.0%)	3 (5.0%)
	4	1 (3.3%)	1 (3.3%)		0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)

^* P < 0.05